)
Visual21 Nov 2025
Data center suppliers
BioCardia (BCDA) investor relations material
BioCardia Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Advanced regulatory submissions for CardiAMP cell therapy and Helix delivery system, with ongoing discussions with FDA and Japan's PMDA for market approval in heart failure indications.
CardiAMP Heart Failure II Phase III trial is accelerating, with four centers enrolling and additional sites onboarding; trial design leverages prior positive data and improved patient selection.
CardiAMP cell therapy for chronic myocardial ischemia showed improved exercise tolerance and reduced angina in trial patients; results being prepared for publication.
CardiALLO allogeneic cell therapy phase 1/2 trial advanced with no safety concerns in the low dose cohort; Phase 2 development planned in the US and Japan.
Partnership with CART-Tech to develop Heart3D Fusion Imaging for biotherapeutic delivery, with promising preclinical results and clinical advancement planned for 2026.
Financial highlights
Net loss for Q3 2025 was $1.5 million, down from $1.7 million in Q3 2024; net loss for nine months ended September 2025 was $6.2 million, up from $5.7 million year-over-year.
Research and development expenses rose to $936,000 in Q3 2025 from $931,000 in Q3 2024, and to $3.8 million for the nine months ended September 2025 from $3.0 million in the prior year period.
Selling, general and administrative expenses decreased to $0.6 million in Q3 2025 from $0.8 million in Q3 2024, and to $2.4 million for the nine months ended September 2025 from $2.8 million in the prior year.
Cash and cash equivalents at September 30, 2025, were $5.3 million, providing runway into Q2 2026.
Accumulated deficit reached $166.4 million as of September 30, 2025.
Outlook and guidance
Cash on hand projected to fund operations into Q2 2026 without additional financing; additional capital will be required for operations beyond that.
Anticipate modest R&D expense increase in 2025 as clinical programs advance in the US and Japan.
SG&A expected to remain close to 2024 levels.
Expect Japan PMDA clinical review and FDA meeting request for CardiAMP in Q4 2025; peer-reviewed publications and further trial enrollment milestones in 2026.
Plans to raise capital through equity, debt, or non-dilutive arrangements; failure to secure funding may require cost reductions or program delays.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BioCardia earnings date
Q4 20251 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BioCardia Inc. is a clinical-stage regenerative medicine company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's leading therapeutic candidate, CardiAMP, is an autologous mononuclear cell therapy system designed for treating heart failure and chronic myocardial ischemia, alongside an allogeneic cell therapy for cardiac and pulmonary disease. BioCardia is also advancing an allogeneic cells therapeutic platform, in Phase I/II trial for ischemic heart failure treatment. Additionally, BioCardia offers the Helix biotherapeutic delivery system for precise heart muscle treatments and Morph deflectable guides and sheaths. The company is headquartered in Sunnyvale, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage